A Study With Gemcitabine, Cisplatin, and LY293111 in Non-Small Cell Lung Cancer

• Status: Completed
• Trial end date: 2005-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the effectiveness and side effects of LY293111 given in combination with gemcitabine and cisplatin in patients with non-small cell lung cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Cisplatin; Gemcitabine

Criteria

Inclusion Criteria:

• Non-Small Cell Lung Cancer, Stage IIIB or IV that is not amenable to either surgery of curative intent or radiation therapy

• Tumor that can be measured by x-ray or scan

• Adequate organ function

Exclusion Criteria:

• Inability to swallow capsules

• Documented brain metastases

• Prior chemotherapy or biological therapy for this disease